Related Experiment Video

Updated: Aug 24, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

[Changes in muscarinic receptors of the aging bladder]

K-E Andersson1, A Schröder

  • 1Department of Clinical and Experimental Pharmacology, Lund University Hospital, Lund, Sweden. karl-erik.andersson@klinfarm.lu.se

Der Urologe. Ausg. A
|April 21, 2004
PubMed

Insights

Overactive bladder (OAB) prevalence rises with age, yet treatments remain limited. While muscarinic receptors are key to OAB, age-related changes in bladder muscle contraction don't significantly alter antimuscarinic drug effectiveness.

Area of Science:

  • Urology
  • Pharmacology
  • Gerontology

Context:

  • Overactive bladder syndrome (OAB) prevalence increases with age.
  • Current OAB treatments are often unsatisfactory.
  • Muscarinic receptor antagonists are the primary effective drug therapy for OAB.

Purpose:

  • To investigate the role of muscarinic receptors in OAB pathogenesis.
  • To examine age-dependent changes in muscarinic receptor function and detrusor contraction.
  • To clarify the clinical implications of these age-related changes on OAB treatment efficacy.

Summary:

  • Muscarinic receptors are crucial for detrusor muscle contraction in both normal and overactive bladders.
  • Age-related studies show a decrease in muscarinic receptor-mediated contraction and an increase in ATP (purinergic) components.
  • Despite these physiological shifts, clinical evidence does not indicate significant age-dependent changes in the efficacy of antimuscarinic OAB treatments.

Impact:

  • Highlights the complex age-related physiological changes in bladder function.
  • Underscores the continued importance of muscarinic receptors in OAB pathophysiology.
  • Suggests that current antimuscarinic therapies may remain effective across different age groups for OAB management.

More Related Videos

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation08:08

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

Published on: August 21, 2012

A Decentralized (Ex Vivo) Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling06:36

A Decentralized (Ex Vivo) Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling

Published on: November 28, 2019

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
The Micturition Reflex01:26

The Micturition Reflex

Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating urine...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.